A Study of Botensilimab and Balstilimab for Colorectal Cancer
Status:
RECRUITING
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colon cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy.